Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In-stent restenosis (ISR) is one adverse outcome of coronary stent implantation. Although using drug-eluting stents has reduced the rate of ISR, it remains a major problem. Here, we have investigated the relationship between several patient characteristics including serum high sensitive C-reactive protein (hs-CRP) and ISR.
Methods: This was a case-control study comprising 104 individuals with ISR and 202 patients without. Baseline characteristics were collected using a questionnaire. Fasting blood glucose (FBG), serum triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and serum high sensitivity C-reactive protein (hs-CRP) were measured using commercial kits on an auto-analyzer. Data were analyzed using SPSS software and a p value ≤ 0.05 was considered significant.
Results: Diabetes mellitus (p < 0.001), stent type (p = 0.005), serum hs-CRP (p = 0.006), FBG (p = 0.038) and serum TG (p = 0.039) were significantly associated with ISR. The association between hs-CRP and ISR remained significant after adjustment for stent type and DM. For patients with a serum hs-CRP <2.64 mg/dL, ISR was only associated with diabetes mellitus (p = 0.016); while for individuals with a serum hs-CRP ≥2.64 mg/dL, ISR was also associated with the presence of diabetes mellitus, serum triglycerides and stent type.
Conclusion: Higher levels of serum hs-CRP were significantly associated with the occurrence of ISR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carrev.2018.08.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The lncRNA-miRNA-mRNA regulatory network is recognized for its significant role in cardiovascular diseases, yet its involvement in in-stent restenosis (ISR) remains unexplored. Our study aimed to investigate how this regulatory network influences ISR occurrence and development by modulating inflammation and immunity.
Methods: By utilizing data extracted from the Gene Expression Omnibus (GEO) database, we constructed the lncRNA-miRNA-mRNA regulatory network specific to ISR.
Risk factors for coronary in-stent restenosis in Moroccan patients: a retrospective case-control study.
Cell Mol Biol (Noisy-le-grand)
September 2025
Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco.
In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.
View Article and Find Full Text PDFComparative evaluation of the CGuard dual-layer stent and Carotid Wallstent for elective carotid artery stenting: a retrospective multicenter study.
Neuroradiology
September 2025
Department of Diagnostic and Interventional Neuroradiology, Klinikum Solingen, Solingen, Germany.
Purpose: This study aims to evaluate the safety and efficacy of the CGuard dual-layer stent with its mesh embolic protection system (EPS) in elective cases for treatment of internal carotid artery stenosis and compares it to the Carotid Wallstent as benchmark.
Methods: In this retrospective, multicenter study, we analyzed data from consecutive patients who underwent carotid artery stenting with CGuard at two high-volume neurointerventional centers and compared them with prior consecutive patients treated with Carotid Wallstent (CWS), with and without a balloon guiding catheter (BGC) as protection, at the same institutions. Patient demographics, procedural details, clinical complications, early in-stent thrombosis and occlusion rates, and late follow-up restenosis rates were assessed.
Restenosis After Pulmonary Vein Stenting Following Pulmonary Vein Isolation With Nonobstructive General Angioscopy.
JACC Case Rep
September 2025
Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
A 33-year-old male developed pulmonary vein (PV) stenosis 3 months after PV isolation for atrial fibrillation. Stents were implanted in the left superior and inferior PVs, but 2 years later, in-stent restenosis occurred. Intravascular ultrasound and nonobstructive general angioscopy (NOGA) revealed severe ostial stenosis and neointimal hyperplasia.
View Article and Find Full Text PDFThe challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level: a case report.
Eur Heart J Case Rep
September 2025
Cardio-Thoracic-Vascular Department, Cardiology Unit, Azienda Ospedaliera Carlo Poma, ASST Mantova, Str. Lago Paiolo 10, Mantova 46100, Italy.
Background: While advances in technology and procedural techniques have significantly improved outcomes post-PCI, two pharmacological strategies have gained particular attention for their effectiveness in reducing long-term cardiovascular (CV) risk: anti-platelet therapies and lipid-lowering therapies (LLT). The 10-year recurrence risk for major CV events remains as high as 10-30%, due to various pathophysiological pathways collectively known as residual risk (RR), even with optimal CV risk factor management after acute coronary syndrome (ACS). RR includes factors such as elevated lipoprotein(a) [Lp(a)], triglycerides, pro-thrombotic states, hyperglycemia, and persistent subclinical arterial inflammation.
View Article and Find Full Text PDF